What is MSLE's market cap?

Satellos Bioscience Inc. (MSLE) is a listed stock with a live quote. The latest market cap on this page is $8.6M.

Where is Satellos Bioscience Inc. headquartered?

Satellos Bioscience Inc. is headquartered in Toronto, ON.

How do I get MSLE news from the API?

Call GET /v1/news?tickers=MSLE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does MSLE news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MSLE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the MSLE price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email sales@marketnewsapi.com.

MSLE · NASDAQ

Satellos Bioscience Inc.

$6.67 +0.21 (+3.17%)

Company overview

Satellos Bioscience, Inc. is a regenerative medicine company that engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™, leveraging it to identify stem cell-based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012, and is headquartered in Toronto, Canada.

Sector: Healthcare
Industry: Medical - Pharmaceuticals
Exchange: NASDAQ
Market cap: $8.6M
Employees: 14
Headquarters: Toronto, ON
Website: satellos.com
CEO: Francis Gleeson
Listed: May 10, 2024
P/E: -3.88
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: $0.00
Operating income: -$30M
EBITDA: -$30M
Net income: -$28.5M
EPS: -$1.72
Total assets: $75.5M
Total debt: $0.00
Earnings yield: -25.79%

Price chart

MSLE 1D NASDAQ O6.55H6.65L6.39C6.47+0.10 (+1.57%)Vol11.71K

News

Ticker	Type	Headline	Source	Published
MSLESatellos Bioscience Inc.	Press release	Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study	GlobeNewswire	Nov 5, 4:32:02 PM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience	GlobeNewswire	Oct 27, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos to Participate in Upcoming Investor Conferences	GlobeNewswire	Oct 21, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Granted Composition of Matter Patent for Forazapadin	GlobeNewswire	Oct 5, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Announces Completion of Enrollment in BASECAMP	GlobeNewswire	Sep 30, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Stock news	Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages	Defense World	Sep 28, 4:15:53 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development	GlobeNewswire	Sep 24, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos to Present at the 31st Annual Congress of the	GlobeNewswire	Sep 15, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247	GlobeNewswire	Sep 9, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos to Participate in Upcoming Investor Conferences	GlobeNewswire	Sep 1, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress	GlobeNewswire	Aug 13, 5:02:00 PM ET
MSLESatellos Bioscience Inc.	Stock news	Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence	Benzinga	Jul 8, 9:34:20 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247	GlobeNewswire	Jul 8, 6:30:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy	GlobeNewswire	Jun 29, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos to Present Clinical Program Updates at ICNMD 2026	GlobeNewswire	Jun 25, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Press release	Satellos Bioscience Announces Results of Annual Meeting of Shareholders	GlobeNewswire	Jun 17, 5:00:00 PM ET
MSLESatellos Bioscience Inc.	Stock news	Satellos to Participate in Upcoming Investor Conferences	GlobeNewswire	May 27, 7:00:00 AM ET
MSLESatellos Bioscience Inc.	Stock news	Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More	247 Wallst	Apr 6, 7:54:28 AM ET

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.